Manuscript Data Delineate Potential Role of KRAS Oncogene in Patient Selection for Vectibix Treatment
THOUSAND OAKS, Calif., Mar 04, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) today announced that the results from a
biomarker analysis of the pivotal "408" trial were published in the
Journal of Clinical Oncology (JCO). The analysis showed that KRAS
mutations could be used to identify patients who may not respond to
treatment with Vectibix(TM) (panitumumab) monotherapy, the first fully
human anti-epidermal growth factor receptor (EGFr) monoclonal
antibody. These data were previously reported at the European Cancer
Conference in 2007 and the Gastrointestinal Cancer Symposium in
January 2008. The paper was made available early online on the JCO Web
site and will be in the April 2008 print edition.
These findings are the first published results from a Phase 3
randomized, controlled clinical trial to affirm the link between
non-mutated (wild-type) KRAS in tumors, and the efficacy of treatment
with anti-EGFr in patients with metastatic colorectal cancer (mCRC).
The analysis met primary and secondary endpoints by demonstrating that
the effect of Vectibix on progression-free survival (PFS) was
different in patients according to the mutational status of the KRAS
gene in their tumors. The effect of Vectibix on PFS and response rate
appeared to be confined exclusively to the patients whose tumors
harbor normal, non-mutated KRAS.
"These results validate the importance of the KRAS oncogene in
identifying appropriate patients for treatment with Vectibix
monotherapy in the advanced colorectal cancer setting," said Roger M.
Perlmutter, M.D., Ph.D., executive vice president of Research and
Development at Amgen. "We have developed the first prospective
clinical trials with KRAS in earlier lines of mCRC to enhance our
understanding of this biomarker and its potential application. We also
are continuing to investigate the role of other markers to further
refine patient selection."
These analyses were derived from the pivotal "408" trial, which
had shown that Vectibix monotherapy was significantly more effective
than best supportive care in treating mCRC patients in the
chemorefractory setting. Activating KRAS mutations were detected using
real-time polymerase chain reaction (PCR) on DNA derived mostly from
fixed, archived tumor sections.
Results from studies performed over the last twenty-five years
indicate that KRAS plays an important role in cell growth regulation.
In mCRC, the EGFr transmits signals through a set of intracellular
proteins. Upon reaching the nucleus, these signals instruct the cancer
cell to reproduce and metastasize, leading to cancer progression.
Anti-EGFr therapies work by blocking the activation of EGFr, thereby
inhibiting downstream events that lead to malignant signaling.
However, it is hypothesized that in patients with tumors harboring a
mutated KRAS gene, the KRAS protein is always turned "on," regardless
of whether the EGFr has been activated or therapeutically inhibited.
Vectibix was approved in the United States (U.S.) in September
2006 as a single agent for the treatment of patients with EGFr
expressing mCRC after disease progression on or following
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing
chemotherapy regimens. The effectiveness of Vectibix as a single agent
for the treatment of EGFR-expressing mCRC is based on PFS. Currently
no data are available that demonstrate an improvement in
disease-related symptoms or increased survival with Vectibix. In the
U.S., Vectibix is not approved for use based on KRAS status. In
December 2007, the European Medicines Agency (EMEA) granted a
conditional marketing authorization for Vectibix as monotherapy for
the treatment of patients with EGFr expressing mCRC with non-mutated
KRAS genes after failure of standard chemotherapy regimens. Regulatory
applications in the rest of the world are still pending.
There are currently ongoing Phase 3 trials examining Vectibix in
combination with chemotherapy in the first- and second-line of mCRC.
KRAS and other biomarker analyses have and will continue to be
integrated into the ongoing clinical program studying Vectibix in
earlier lines of mCRC therapy in combination with chemotherapy, as
well as in other tumor types.
Important Product Safety Information - U.S.
Dermatologic toxicities, related to Vectibix blockade of EGF
binding and subsequent inhibition of EGF receptor-mediated signaling
pathways, included but were not limited to dermatitis acneiform,
pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and
skin fissures. Dermatologic toxicities were reported in 89 percent of
patients treated with Vectibix and were severe in 12 percent of
patients. Severe dermatologic toxicities were complicated by
infection, including sepsis, septic death, and abscesses requiring
incisions and drainage. Vectibix may need to be withheld or
discontinued for severe dermatologic toxicities.
Severe infusion reactions occurred with Vectibix in approximately
1 percent of patients. Severe infusion reactions were identified as
anaphylactic reactions, bronchospasm, fever, chills, and hypotension.
Although fatal infusion reactions have not been reported with
Vectibix, they have occurred with other monoclonal antibody products.
Severe infusion reactions require stopping the infusion and possibly
permanently discontinuing Vectibix, depending on the severity and/or
persistence of the reaction.
Important Product Safety Information - European Union
Dermatologic related reactions, a pharmacologic effect observed
with EGFr inhibitors, are experienced with nearly all patients
(approximately 90 percent) treated with Vectibix. The majority of
dermatological reactions are mild to moderate in nature. In clinical
studies, subsequent to the development of severe dermatological
reactions (including stomatitis), infectious complications including
sepsis, in rare cases leading to death, and local abscesses requiring
incisions and drainage were reported. Patients who have severe
dermatologic reactions or who develop worsening reactions whilst
receiving Vectibix should be monitored for the development of
inflammatory or infectious sequelae, and appropriate treatment
Amgen discovers, develops, manufactures and delivers innovative
human therapeutics. A biotechnology pioneer since 1980, Amgen was one
of the first companies to realize the new science´s promise by
bringing safe and effective medicines from lab, to manufacturing
plant, to patient. Amgen therapeutics have changed the practice of
medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to
dramatically improve people´s lives. To learn more about our
pioneering science and our vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that are
based on management´s current expectations and beliefs and are subject
to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described. All
statements, other than statements of historical fact, are statements
that could be deemed forward-looking statements, including estimates
of revenues, operating margins, capital expenditures, cash, other
financial metrics, expected legal, arbitration, political, regulatory
or clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve significant
risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC)
reports filed by Amgen, including Amgen´s most recent annual report on
Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.
Please refer to Amgen´s most recent Forms 10-K, 10-Q and 8-K for
additional information on the uncertainties and risk factors related
to our business. Unless otherwise noted, Amgen is providing this
information as of March 4, 2008 and expressly disclaims any duty to
update information contained in this news release.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify safety, side effects or manufacturing
problems with our products after they are on the market. Our business
may be impacted by government investigations, litigation and products
liability claims. We depend on third parties for a significant portion
of our manufacturing capacity for the supply of certain of our current
and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.
In addition, sales of our products are affected by the
reimbursement policies imposed by third-party payors, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and healthcare
cost containment as well as U.S. legislation affecting pharmaceutical
pricing and reimbursement. Government and others´ regulations and
reimbursement policies may affect the development, usage and pricing
of our products. In addition, we compete with other companies with
respect to some of our marketed products as well as for the discovery
and development of new products. We believe that some of our newer
products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Our
products may compete against products that have lower prices,
established reimbursement, superior performance, are easier to
administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors and there can be no guarantee of our ability to obtain or
maintain patent protection for our products or product candidates. We
cannot guarantee that we will be able to produce commercially
successful products or maintain the commercial success of our existing
products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of
our products or product candidates. Further, the discovery of
significant problems with a product similar to one of our products
that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business
and results of operations.
The scientific information discussed in this news release relating
to new indications for our products is preliminary and investigative
and is not part of the labeling approved by the U.S. Food and Drug
Administration (FDA) for the products. The products are not approved
for the investigational use(s) discussed in this news release, and no
conclusions can or should be drawn regarding the safety or
effectiveness of the products for these uses. Only the FDA can
determine whether the products are safe and effective for these uses.
Healthcare professionals should refer to and rely upon the
FDA-approved labeling for the products, and not the information
discussed in this news release.
Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)